Venclyxto - direct healthcare professional communication (DHPC)

venetoclax

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Venclyxto - (venetoclax) film coated tablets: Updated recommendations on tumour lysis syndrome (TLS) in CLL patients

Key facts

• Medicine name:
  Venclyxto
• Active substance:
  venetoclax
• Therapeutic area (MeSH):
  Leukemia, Lymphocytic, Chronic, B-Cell
• Procedure number:
  EMEA/H/C/004106/II/0031
• Regulatory outcome:
  Variation
• DHPC type:
  Type II variation
• Human ATC codes:
  L01XX52
• Dissemination date:
  10/06/2021